When was Plaquetec founded?

Plaquetec was founded in 2008 and raised its 1st funding round 16 years after it was founded.

Where is Plaquetec located?

Plaquetec is headquartered in Cambridge, United Kingdom.

Which legal entities is Plaquetec associated with?

Plaquetec is associated with Plaquetec Limited.

How many employees does Plaquetec have?

As of Aug 31, 2026, the latest employee count at Plaquetec is 5.

Is Plaquetec a funded company?

Plaquetec is a funded company, having raised a total of $13M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 30, 2024.

When was the latest funding round of Plaquetec?

Plaquetec's latest funding was a $***** Series A round on Apr 27, 2026, with participation from 0 investor. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $80.8M in funding in 2026 to date.

Where does Plaquetec rank among its competitors?

Plaquetec ranks 13th amongst 96 active competitors, of which 30 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Plaquetec, which secured $5M in Apr, 2026.

Who are the top competitors of Plaquetec?

Plaquetec's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Plaquetec secured the most recent funding round in April, 2026.

Plaquetec - 2026 Company Profile, Team, Funding, Competitors & Financials

Plaquetec is a series A company based in Cambridge (United Kingdom), founded in 2008. It operates as a Developer of a method to profile the biology of coronary artery. Plaquetec has raised $13M in funding from Future Fund. The company has 96 active competitors, including 30 funded and 17 that have exited. Its top competitors include companies like Seer, Tango Therapeutics and Maze Therapeutics.

Company Details

Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.

Website: www.plaquetec.com/
Email ID: *****@plaquetec.com

Key Metrics

Founded Year

2008

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$13M in 2 rounds

Latest Funding Round

Series A, Apr 27, 2026, $*****

Investors

Future Fund & 23 more

Ranked

13^th among 96 active competitors

Employee Count

5 as on Aug 31, 2026

Similar Companies

Seer & 123 more

View Plaquetec's full profile

Plaquetec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Plaquetec Limited CIN: 6212970 , Germany, Active	Apr 15, 2007	-	2 (As on Jan 31, 2022)

Plaquetec has raised a total funding of $13M over 2 rounds. Its first funding round was on Apr 30, 2024. Plaquetec has 3 institutional investors and 21 angel investors.

Here is the list of recent funding rounds of Plaquetec:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 27, 2026	7782486	Series A	7005888	3113030	8338380	9576180
Apr 30, 2024	6874718	Series A	9861621	1873612	Future Fund	3251331

Access funding benchmarks and valuations. Sign up today!

View details of Plaquetec's funding rounds and investors

Plaquetec's Board of Directors

Plaquetec's board has 3 active members. Christopher John Latimer Haynes, Martin Gordon Robert Stapleton and Simon Williams are independent board members.

Here is the list of Plaquetec's board of directors:

Name	Type	Representing	Status	Duration
Christopher John Latimer Haynes	Independent board member	-	Current	19y 5m
swketdz	Independent board member	-	Current	4y 2m
vwbzyzr	Independent board member	-	Current	8y 2m

Plaquetec's employee count trend

Plaquetec has 5 employees as of Aug 26. Here is Plaquetec's employee count trend over the years:

Uncover Plaquetec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Plaquetec include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Plaquetec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
8th	Proteomics International 2001, Perth (Australia), Public	Medical technology company at the forefront of predictive diagnostics and bio-analytical services	-	MTPConnect, NorthStar Impact	55/100
9th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	55/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
13th	Plaquetec 2008, Cambridge (United Kingdom), Series A	Developer of a method to profile the biology of coronary artery	$13M	Future Fund, Ipex Capital & 22 others	51/100